110 related articles for article (PubMed ID: 23936455)
1. TP53 and let-7a micro-RNA regulate K-Ras activity in HCT116 colorectal cancer cells.
Luu C; Heinrich EL; Duldulao M; Arrington AK; Fakih M; Garcia-Aguilar J; Kim J
PLoS One; 2013; 8(8):e70604. PubMed ID: 23936455
[TBL] [Abstract][Full Text] [Related]
2. Mutations in specific codons of the KRAS oncogene are associated with variable resistance to neoadjuvant chemoradiation therapy in patients with rectal adenocarcinoma.
Duldulao MP; Lee W; Nelson RA; Li W; Chen Z; Kim J; Garcia-Aguilar J
Ann Surg Oncol; 2013 Jul; 20(7):2166-71. PubMed ID: 23456389
[TBL] [Abstract][Full Text] [Related]
3. Determination of synthetic lethal interactions in KRAS oncogene-dependent cancer cells reveals novel therapeutic targeting strategies.
Steckel M; Molina-Arcas M; Weigelt B; Marani M; Warne PH; Kuznetsov H; Kelly G; Saunders B; Howell M; Downward J; Hancock DC
Cell Res; 2012 Aug; 22(8):1227-45. PubMed ID: 22613949
[TBL] [Abstract][Full Text] [Related]
4. The RAS oncogene in brain tumors and the involvement of let-7 microRNA.
Messina S
Mol Biol Rep; 2024 Apr; 51(1):531. PubMed ID: 38637419
[TBL] [Abstract][Full Text] [Related]
5. A polymorphism in a let-7 microRNA binding site of KRAS in women with endometriosis.
Grechukhina O; Petracco R; Popkhadze S; Massasa E; Paranjape T; Chan E; Flores I; Weidhaas JB; Taylor HS
EMBO Mol Med; 2012 Mar; 4(3):206-17. PubMed ID: 22307873
[TBL] [Abstract][Full Text] [Related]
6. Transcriptional Regulation of miR-31 by Oncogenic KRAS Mediates Metastatic Phenotypes by Repressing RASA1.
Kent OA; Mendell JT; Rottapel R
Mol Cancer Res; 2016 Mar; 14(3):267-77. PubMed ID: 26747707
[TBL] [Abstract][Full Text] [Related]
7. PLEKHA7 signaling is necessary for the growth of mutant KRAS driven colorectal cancer.
Jeung HC; Puentes R; Aleshin A; Indarte M; Correa RG; Bankston LA; Layng FIAL; Ahmed Z; Wistuba I; Yao Y; Duenas DG; Zhang S; Meuillet EJ; Marassi F; Liddington RC; Kirkpatrick L; Powis G
Exp Cell Res; 2021 Dec; 409(2):112930. PubMed ID: 34800542
[TBL] [Abstract][Full Text] [Related]
8. Gene Therapy Targeting p53 and KRAS for Colorectal Cancer Treatment: A Myth or the Way Forward?
Hasbullah HH; Musa M
Int J Mol Sci; 2021 Nov; 22(21):. PubMed ID: 34769370
[TBL] [Abstract][Full Text] [Related]
9. Regulation of pancreatic cancer growth by superoxide.
Du J; Nelson ES; Simons AL; Olney KE; Moser JC; Schrock HE; Wagner BA; Buettner GR; Smith BJ; Teoh ML; Tsao MS; Cullen JJ
Mol Carcinog; 2013 Jul; 52(7):555-67. PubMed ID: 22392697
[TBL] [Abstract][Full Text] [Related]
10. KRAS and YAP1 converge to regulate EMT and tumor survival.
Shao DD; Xue W; Krall EB; Bhutkar A; Piccioni F; Wang X; Schinzel AC; Sood S; Rosenbluh J; Kim JW; Zwang Y; Roberts TM; Root DE; Jacks T; Hahn WC
Cell; 2014 Jul; 158(1):171-84. PubMed ID: 24954536
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of KRAS Gene Expression and LCS6 Variant in Genomic and Cell-Free DNA of Iranian Women With Endometriosis.
Farahani MS; Shahbazi S; Moghaddam SA; Mahdian R
Reprod Sci; 2015 Jun; 22(6):679-84. PubMed ID: 25361550
[TBL] [Abstract][Full Text] [Related]
12. Morindone as a potential therapeutic compound targeting TP53 and KRAS mutations in colorectal cancer cells.
Chee CW; Mohd Hashim N; Nor Rashid N
Chem Biol Interact; 2024 Apr; 392():110928. PubMed ID: 38423379
[TBL] [Abstract][Full Text] [Related]
13. TP53 regulates miRNA association with AGO2 to remodel the miRNA-mRNA interaction network.
Krell J; Stebbing J; Carissimi C; Dabrowska AF; de Giorgio A; Frampton AE; Harding V; Fulci V; Macino G; Colombo T; Castellano L
Genome Res; 2016 Mar; 26(3):331-41. PubMed ID: 26701625
[TBL] [Abstract][Full Text] [Related]
14. Defining function of wild-type and three patient-specific
Chen J; Baxi K; Lipsitt AE; Hensch NR; Wang L; Sreenivas P; Modi P; Zhao XR; Baudin A; Robledo DG; Bandyopadhyay A; Sugalski A; Challa AK; Kurmashev D; Gilbert AR; Tomlinson GE; Houghton P; Chen Y; Hayes MN; Chen EY; Libich DS; Ignatius MS
Elife; 2023 Jun; 12():. PubMed ID: 37266578
[TBL] [Abstract][Full Text] [Related]
15. Integrative Molecular Characterization of Resistance to Neoadjuvant Chemoradiation in Rectal Cancer.
Kamran SC; Lennerz JK; Margolis CA; Liu D; Reardon B; Wankowicz SA; Van Seventer EE; Tracy A; Wo JY; Carter SL; Willers H; Corcoran RB; Hong TS; Van Allen EM
Clin Cancer Res; 2019 Sep; 25(18):5561-5571. PubMed ID: 31253631
[TBL] [Abstract][Full Text] [Related]
16. Colorectal Cancer Is Associated with the Presence of Cancer Driver Mutations in Normal Colon.
Matas J; Kohrn B; Fredrickson J; Carter K; Yu M; Wang T; Gui X; Soussi T; Moreno V; Grady WM; Peinado MA; Risques RA
Cancer Res; 2022 Apr; 82(8):1492-1502. PubMed ID: 35425963
[TBL] [Abstract][Full Text] [Related]
17. Molecular Classification of Appendiceal Adenocarcinoma.
Foote MB; Walch H; Chatila W; Vakiani E; Chandler C; Steinruecke F; Nash GM; Stadler Z; Chung S; Yaeger R; Braghrioli MI; Shia J; Kemel Y; Maio A; Sheehan M; Rousseau B; Argilés G; Berger M; Solit D; Schultz N; Diaz LA; Cercek A
J Clin Oncol; 2023 Mar; 41(8):1553-1564. PubMed ID: 36493333
[TBL] [Abstract][Full Text] [Related]
18. Mitomycin C and its analog trigger cytotoxicity in MCF-7 and K562 cancer cells through the regulation of RAS and MAPK/ERK pathways.
Zacarias O; Clement CC; Cheng SY; Rosas M; Gonzalez C; Peter M; Coopman P; Champeil E
Chem Biol Interact; 2024 May; 395():111007. PubMed ID: 38642817
[TBL] [Abstract][Full Text] [Related]
19.
Coan M; Toso M; Cesaratto L; Rigo I; Borgna S; Dalla Pietà A; Zandonà L; Iuri L; Zucchetto A; Piazza C; Baldassarre G; Spizzo R; Nicoloso MS
Int J Mol Sci; 2023 Sep; 24(18):. PubMed ID: 37762037
[No Abstract] [Full Text] [Related]
20. The genomic landscape of undifferentiated embryonal sarcoma of the liver is typified by C19MC structural rearrangement and overexpression combined with TP53 mutation or loss.
Setty BA; Jinesh GG; Arnold M; Pettersson F; Cheng CH; Cen L; Yoder SJ; Teer JK; Flores ER; Reed DR; Brohl AS
PLoS Genet; 2020 Apr; 16(4):e1008642. PubMed ID: 32310940
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
